Skip to main content

Ingrezza Disease Interactions

There are 4 disease interactions with Ingrezza (valbenazine).

Major

Valbenazine (applies to Ingrezza) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Valbenazine is extensively metabolized after oral administration by the liver. Dosage adjustment of valbenazine 40 mg once daily is recommended for patients with moderate or severe hepatic impairment (Child-Pugh score 7 to 15). Close monitoring of hepatic function is recommended.

References

  1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc. (2017):
Major

Valbenazine (applies to Ingrezza) QT prolongation

Major Potential Hazard, Moderate plausibility. Applicable conditions: Arrhythmias

Valbenazine may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. The use of valbenazine should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, it is recommended to assess the QT interval before increasing the dosage.

References

  1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc. (2017):
Major

Valbenazine (applies to Ingrezza) renal dysfunction

Major Potential Hazard, Moderate plausibility.

The use of valbenazine is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min). Dosage adjustment is not necessary for patients with mild to moderate renal impairment (creatinine clearance 30 to 90 mL/min).

References

  1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc. (2017):
Moderate

VMAT2 inhibitors (applies to Ingrezza) parkinson

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Parkinsonism

The use of vesicular monoamine transporter 2 (VMAT2) inhibitor, such as valbenazine and deutetrabenazine may cause parkinsonism in patients with tardive dyskinesia. These agents should be used with caution in patients with parkinson disease or those presenting with parkinson-like symptoms such as, falls, gait disturbances, tremor, drooling and hypokinesia. It is recommended to reduce the dose or to discontinue treatment in patients who develop clinically significant parkinson-like signs or symptoms while on treatment with these agents.

References

  1. "Product Information. Ingrezza (valbenazine)." Neurocrine Biosciences, Inc. (2017):
  2. "Product Information. Austedo (deutetrabenazine)." Teva Pharmaceuticals USA (2017):

Ingrezza drug interactions

There are 496 drug interactions with Ingrezza (valbenazine).

Ingrezza alcohol/food interactions

There is 1 alcohol/food interaction with Ingrezza (valbenazine).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer